Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC). Radical nephroureterectomy with an ipsilateral bladder cuff is the ...
PURPOSE: The aim of this phase I study was to determine the safety and toxicity profile of gemcitabine administered as an intravesical agent in patients with transitional-cell carcinoma (TCC) of the ...
Transitional cell carcinoma (TCC) is the most common form of urinary bladder cancer in dogs, presenting significant challenges in both diagnosis and management. This high‐grade invasive neoplasm ...
FGFR3 mutated (FGFR3mut+) urothelial carcinoma of bladder (UCB) or upper tract (UTUC): A comparative genomic landscape study. Disparities in the incidence of next-generation sequencing (NGS) among ...
The FDA approval of nivolumab plus cisplatin and gemcitabine marks the first concurrent immunotherapy-chemotherapy combination for the population. The trial showed the combination significantly ...
Neuropathy, skin rash, and hyperglycemia are linked to improved PFS in patients treated with enfortumab vedotin for metastatic urothelial carcinoma. Patients experiencing these side effects had longer ...
The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.
Nat Clin Pract Urol. 2007;4(8):432-443. JD Raman is a Chief Resident in Urology and DS Scherr is an Assistant Professor of Urology at the New York Presbyterian Hospital–Weill Cornell Medical Center, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback